George Elston appointed CFO, corporate development chief of EyePoint Pharmaceuticals

Rachel Popa - Print  |

Specialty biopharmaceutical company EyePoint Pharmaceuticals appointed George O. Elston as CFO and head of corporate development.

Mr. Elston has been a consultant to the company and previously was the chief financial officer and head of corporate development for Enzyvant Therapeutics. At EyePoint, Mr. Elston will be responsible for the company's corporate development initiatives and financial markets. He has more than 25 years of senior and financial leadership in the biopharmaceutical industry.

"EyePoint is delighted to welcome George during this exciting period of momentum for our ongoing commercial launches of Dexycu and Yutiq in the U.S.,” said Nancy Lurker, president and CEO of EyePoint.

More articles on leadership:
11 states with below-average physician numbers & more: 4 workforce insights
8 executive moves at big ASC companies — Tenet, Optum & more
HCA Healthcare names successor to division president, longtime exec: 3 key points

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.